The frequency of moderate or severe exacerbations was also lower for aclidinium 200 μg and 400 μg versus placebo, although the rate ratios did not reach statistical significance (0.74 (p=0.08 ) and 0.72 (p=0.06), respectively) [ 74 ].
← all excerpts
The role of bronchodilator treatment in the prevention of exacerbations of COPD.
1
0.0800
0.0800